These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

147 related articles for article (PubMed ID: 12681206)

  • 1. [Present and future of adjuvant hormone therapy in breast cancer: clinical evidence and clinical trials].
    Zapatero A; Martín de Vidales C; Pérez-Torrubia A
    Rev Clin Esp; 2003 Apr; 203(4):202-6. PubMed ID: 12681206
    [No Abstract]   [Full Text] [Related]  

  • 2. Adjuvant aromatase inhibitor therapy for early breast cancer: A review of the most recent data.
    Grana G
    J Surg Oncol; 2006 Jun; 93(7):585-92. PubMed ID: 16705732
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Reducing the risk for breast cancer recurrence after completion of tamoxifen treatment in postmenopausal women.
    Jahanzeb M
    Clin Ther; 2007 Aug; 29(8):1535-47. PubMed ID: 17919537
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The Breast International Group 1-98 trial: big results for women with hormone-sensitive early breast cancer.
    Monnier AM
    Expert Rev Anticancer Ther; 2007 May; 7(5):627-34. PubMed ID: 17492927
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Letrozole compared with tamoxifen as initial adjuvant therapy for breast cancer.
    Buzdar AU
    J Clin Oncol; 2007 May; 25(15):2147-8; author reply 2148. PubMed ID: 17513830
    [No Abstract]   [Full Text] [Related]  

  • 6. Anastrozole.
    Cuzick J
    Drugs Today (Barc); 2005 Apr; 41(4):227-39. PubMed ID: 16034487
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Sequential hormonal therapy for metastatic breast cancer after adjuvant tamoxifen or anastrozole.
    Carlson RW; Henderson IC
    Breast Cancer Res Treat; 2003; 80 Suppl 1():S19-26; discussion S27-8. PubMed ID: 14535531
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Current developments in hormonal therapy of breast cancer.
    Buzdar AU
    Clin Breast Cancer; 2004 Sep; 5 Suppl 1():S4-5. PubMed ID: 15347432
    [No Abstract]   [Full Text] [Related]  

  • 9. Letrozole or tamoxifen in early breast cancer.
    Erban JK
    N Engl J Med; 2006 Apr; 354(14):1528-30; author reply 1528-30. PubMed ID: 16602148
    [No Abstract]   [Full Text] [Related]  

  • 10. [Optimal adjuvant hormone therapy in postmenopausal women with hormone-sensitive mammary carcinoma: tamoxifen and the aromatase inhibitors anastrozole, exemestane and letrozole].
    van Nes JG; Seynaeve C; van de Velde CJ; Nortier JW
    Ned Tijdschr Geneeskd; 2006 Dec; 150(52):2863-9. PubMed ID: 17319217
    [TBL] [Abstract][Full Text] [Related]  

  • 11. World's largest breast cancer treatment trial supports anastrozole use.
    Oncology (Williston Park); 2002 Jan; 16(1):63. PubMed ID: 11831610
    [No Abstract]   [Full Text] [Related]  

  • 12. Re: Randomized trial of letrozole following tamoxifen as extended adjuvant therapy in receptor-positive breast cancer: updated findings from NCIC CTG MA.17.
    Vakaet L
    J Natl Cancer Inst; 2006 Aug; 98(16):1162; author reply 1162-3. PubMed ID: 16912269
    [No Abstract]   [Full Text] [Related]  

  • 13. Assessing the risk of bone fracture among postmenopausal women who are receiving adjuvant hormonal therapy for breast cancer.
    Bell R; Lewis J
    Curr Med Res Opin; 2007 May; 23(5):1045-51. PubMed ID: 17519070
    [TBL] [Abstract][Full Text] [Related]  

  • 14. 'Arimidex' (anastrozole) versus tamoxifen as adjuvant therapy in postmenopausal women with early breast cancer--efficacy overview.
    Buzdar AU;
    J Steroid Biochem Mol Biol; 2003 Sep; 86(3-5):399-403. PubMed ID: 14623537
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Aromatase inhibitors continue their ATAC on tamoxifen.
    Nicholls H
    Trends Mol Med; 2002; 8(4 Suppl):S12-3. PubMed ID: 11927281
    [No Abstract]   [Full Text] [Related]  

  • 16. Letrozole: advancing hormone therapy in breast cancer.
    Lee RJ; Armstrong AC; Wardley AM
    Womens Health (Lond); 2012 Nov; 8(6):611-8. PubMed ID: 23181527
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Three years' follow-up from the ATAC trial is sufficient to change clinical practice: a debate.
    Aapro MS; Forbes JF
    Breast Cancer Res Treat; 2003; 80 Suppl 1():S3-11; discussion S13-8. PubMed ID: 14535530
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Letrozole improves disease-free survival vs tamoxifen in adjuvant treatment of early breast cancer.
    Oncology (Williston Park); 2005 Mar; 19(3):277, 360. PubMed ID: 15828547
    [No Abstract]   [Full Text] [Related]  

  • 19. Anastrozole as an adjuvant endocrine treatment for postmenopausal patients with breast cancer: emerging data.
    Buzdar AU; Cuzick J
    Clin Cancer Res; 2006 Feb; 12(3 Pt 2):1037s-1048s. PubMed ID: 16467122
    [TBL] [Abstract][Full Text] [Related]  

  • 20. American Society of Clinical Oncology technology assessment on the use of aromatase inhibitors as adjuvant therapy for women with hormone receptor-positive breast cancer: status report 2002.
    Winer EP; Hudis C; Burstein HJ; Chlebowski RT; Ingle JN; Edge SB; Mamounas EP; Gralow J; Goldstein LJ; Pritchard KI; Braun S; Cobleigh MA; Langer AS; Perotti J; Powles TJ; Whelan TJ; Browman GP
    J Clin Oncol; 2002 Aug; 20(15):3317-27. PubMed ID: 12149306
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.